Matt Phipps Analyst PerformancePartner, Group Head of Biotechnology Equity Research at William BlairMatt Phipps is a stock analyst at William Blair focused in the medical sector, covering 16 publicly traded companies. Over the past year, Matt Phipps has issued 9 stock ratings, including buy and hold recommendations. While full access to Matt Phipps' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt Phipps' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings32 Last 8 YearsBuy Recommendations81.25% 26 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution32RatingsDistribution of strong buy, buy, hold, and sell ratings by Matt Phipps.RatingPercentageCount Strong Buy0.0%0 ratings Buy81.3%26 ratings Hold18.8%6 ratings Sell0.0%0 ratingsOut of 32 total stock ratings issued by Matt Phipps at William Blair, the majority (81.3%) have been Buy recommendations, followed by 18.8% Hold.Best & Worst CallsBest Call0000.0%DVAXMar 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AUTLJun 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ93.8% of companies on NASDAQ15 companiesNYSE6.3% of companies on NYSE1 companyMatt Phipps, an analyst at William Blair, currently covers 16 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies93.8%Manufacturing1 company6.3%Matt Phipps of William Blair specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies81.3%MED - DRUGS2 companies12.5%Miscellaneous1 company6.3% About Matt PhippsMatt Phipps, Ph.D., partner and group head of biotechnology equity research, joined William Blair in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. In the 2019 StarMine Analyst Awards from Refinitiv, Matt was ranked the No. 1 earnings estimator in biotechnology and No. 3 across all industries. He earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S. in physics in medicine from the University of Notre Dame.Follow on LinkedIn Matt Phipps' Ratings History at William Blair Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCMPXCompass Therapeutics3/5/2026Reiterated Rating$5.65Outperform$0.0000.00% ROICMPXCompass Therapeutics1/5/2026Initiated Coverage$5.17Outperform$0.0000.00% ROIDVAXDynavax Technologies12/24/2025Downgrade$15.40Hold$0.0000.00% ROIEVMNEvommune12/1/2025Initiated Coverage$20.71Outperform$0.0000.00% ROIKZRKezar Life Sciences10/17/2025Reiterated Rating$4.17Market Perform$0.0000.00% ROICLYMClimb Bio10/16/2025Initiated Coverage$1.94Outperform$0.0000.00% ROIINSMInsmed8/20/2025Initiated Coverage$127.21Outperform$0.0000.00% ROIINKTMiNK Therapeutics7/11/2025Downgrade$64.17Market Perform$0.0000.00% ROIJSPRJasper Therapeutics7/7/2025Reiterated Rating$3.27Market Perform$0.0000.00% ROICNTXContext Therapeutics4/21/2025Initiated Coverage$0.84Outperform$0.0000.00% ROIXNCRXencor4/21/2025Initiated Coverage$9.70Outperform$00.0000.00% ROIGMABGenmab A/S3/11/2025Upgrade$21.98Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
